Related Experiment Videos
Money matters in epilepsy
1Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, 695011, India.
Neurology India
|January 9, 2001
Summary
The rising cost of epilepsy care, particularly newer drugs and surgery, necessitates careful economic evaluation. While newer treatments offer benefits, their cost-effectiveness varies, especially for intractable seizures and quality of life improvements.
Area of Science:
- Health Economics
- Neurology
- Pharmacoeconomics
Background:
- Epilepsy care costs have significantly increased due to newer anti-epileptic drugs (AEDs) and advanced treatment strategies.
- Direct medical costs include expensive newer AEDs, presurgical evaluations, and epilepsy surgery.
- Indirect societal costs, such as lost productivity and premature mortality, far exceed direct medical expenses.
Purpose of the Study:
- To discuss the economic appraisal principles for epilepsy management.
- To evaluate the cost-effectiveness of newer epilepsy treatments versus conventional ones.
- To provide physicians with data for informed practice regarding epilepsy interventions.
Main Methods:
- Review of economic appraisal principles in epilepsy care.
- Analysis of cost-benefit and cost-utility of newer AEDs and surgical interventions.
- Discussion of existing literature on the economic impact of epilepsy treatments.
Main Results:
- Newer AEDs may not justify increased costs in unselected epilepsy populations but show superiority in intractable cases.
- The high initial costs of presurgical evaluation and epilepsy surgery can be offset by improved quality-adjusted life years.
- Limited data currently exists for physicians to guide economic decision-making in epilepsy practice.
Conclusions:
- Economic evaluation is crucial for assessing the true utility of epilepsy interventions.
- Cost-effectiveness of newer epilepsy treatments is context-dependent, particularly for specific patient subgroups.
- Further research and data are needed to support evidence-based economic decision-making in clinical epilepsy management.